Statement of Changes in Beneficial Ownership (4)
August 18 2021 - 07:39PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Nussbaum Robert L |
2. Issuer Name and Ticker or Trading Symbol
Invitae Corp
[
NVTA
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer |
(Last)
(First)
(Middle)
C/O INVITAE CORPORATION, 1400 16TH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/16/2021 |
(Street)
SAN FRANCISCO, CA 94103
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 8/16/2021 | | S | | 21231 (1) | D | $25.4172 (2) | 246050 (3)(4) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Represents the sale of shares to cover tax withholding obligations associated with the vesting and settlement of restricted stock units. |
(2) | Represents a weighted average sale price. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold. |
(3) | Includes an aggregate of 84,134 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
(4) | In addition to the transaction being reported, the total amount of securities is 402 shares greater than the reporting person's prior report, which reflects (a) the sale of an additional 66 shares on February 13, 2017, which number of shares subject to the sale was incorrectly reported in a Form 4 filed on February 15, 2017, (b) the sale of an additional 1,198 shares on May 15, 2018, which number of shares subject to the sale was incorrectly reported in a Form 4 filed on May 16, 2018 and (c) an unreported exercise of options for 1,666 shares of common stock, which occurred on January 3, 2017. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Nussbaum Robert L C/O INVITAE CORPORATION 1400 16TH STREET SAN FRANCISCO, CA 94103 |
|
| Chief Medical Officer |
|
Signatures
|
/s/ Thomas R. Brida, Attorney-in-Fact | | 8/18/2021 |
**Signature of Reporting Person | Date |
Invitae (NYSE:NVTA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Invitae (NYSE:NVTA)
Historical Stock Chart
From Mar 2023 to Mar 2024